These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 3542743)
1. Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group Study. Alberts DS; Mason NL; O'Toole RV; Hilgers RD; Rivkin SE; Boutselis JG; Pugh RP; Vaitkevicius VK; Green JB; Oishi N Gynecol Oncol; 1987 Feb; 26(2):193-201. PubMed ID: 3542743 [TBL] [Abstract][Full Text] [Related]
2. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Pautier P; Genestie C; Fizazi K; Morice P; Mottet C; Haie-Meder C; Le Cesne A; Lhommé C Int J Gynecol Cancer; 2002; 12(6):749-54. PubMed ID: 12445254 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus. Resnik E; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT Gynecol Oncol; 1995 Mar; 56(3):370-5. PubMed ID: 7705670 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Papadimitriou CA; Dimopoulos MA; Giannakoulis N; Sarris K; Vassilakopoulos G; Akrivos T; Voulgaris Z; Vlahos G; Diakomanolis E; Michalas S Cancer; 1997 Jun; 79(12):2391-5. PubMed ID: 9191528 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma. Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111 [TBL] [Abstract][Full Text] [Related]
8. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Long HJ; Rayson S; Podratz KC; Abu-Ghazaleh S; Suman V; Hartmann LC; Levitt R; Nair S; Hatfield AK; Knost JA Am J Clin Oncol; 2002 Dec; 25(6):547-51. PubMed ID: 12477995 [TBL] [Abstract][Full Text] [Related]
9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W; J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299 [TBL] [Abstract][Full Text] [Related]
11. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183 [TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Pasmantier MW; Coleman M; Silver RT; Mamaril AP; Quiguyan CC; Galindo A Cancer Treat Rep; 1985 May; 69(5):539-42. PubMed ID: 4039980 [TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913 [TBL] [Abstract][Full Text] [Related]
14. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897 [TBL] [Abstract][Full Text] [Related]
15. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211 [TBL] [Abstract][Full Text] [Related]
16. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853 [TBL] [Abstract][Full Text] [Related]
17. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. Igawa M; Ohkuchi T; Ueki T; Ueda M; Okada K; Usui T J Urol; 1990 Sep; 144(3):662-5. PubMed ID: 2388322 [TBL] [Abstract][Full Text] [Related]
18. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Tummarello D; Graziano F; Isidori P; Cellerino R Cancer Chemother Pharmacol; 1995; 35(3):249-53. PubMed ID: 7528646 [TBL] [Abstract][Full Text] [Related]
19. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck. Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]